Meeting
2017 ASCO Annual Meeting
A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Boston, MA
Dejan Juric , Stephanie Faucette , Ling Wang , Huifeng Niu , Karuppiah Kannan , Kate Stumpo , Yuanxin Rong , Yaping Shou , John J. Nemunaitis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02834247
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS3104)
DOI
10.1200/JCO.2017.35.15_suppl.TPS3104
Abstract #
TPS3104
Poster Bd #
192b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Preliminary safety, efficacy, and pharmacokinetics (PK) results of KN046 (bispecific anti-PD-L1/CTLA4) from a first-in-human study in subjects with advanced solid tumors.
First Author: Jermaine Coward
Poster
2024 ASCO Annual Meeting
Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.
First Author: Manish R. Patel
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang
Poster
2023 ASCO Annual Meeting
A phase 1a/b study of BR101801, a PI3K γ/δ and DNA PK triple inhibitor, in adult patients with advanced hematologic malignancies.
First Author: Bong-Seog Kim